NC-762 is under clinical development by NextCure and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer). According to GlobalData, Phase II drugs for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) have a 45% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how NC-762’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NC-762 overview
NC-762 is under development for the treatment of solid tumors including non-small cell lung cancer, HER2 positive breast cancer, melanomat, endometrial cancer, pancreatic cancer, prostate cancer and ovarian cancer. It is administered through intravenous route. The therapeutic candidate is development is based on functional, integrated, next cure discovery in immuno-oncology (FIND-IO) technology platform. It acts by targets B7-H4.
NextCure overview
NextCure is a biopharmaceutical company that develops immune medicines to treat cancer and other immune-related diseases. The company’s product portfolio includes the FIND-IO technology platform to discover and understand targets and structural components of immune cells and their functional impact in order to develop immune medicines. Its pipeline products include protein drugs such as NC762, NC525 and NC410 are expressed on highly immunosuppressive cells and tumor cells. It is also pursuing partnering opportunities with pharmaceutical and biotechnology companies to discover and develop biologic-based therapeutics for the treatment of cancer, autoimmune and neurological disorders and expanding to a variety of therapeutic areas. NextCure is headquartered in Beltsville, Maryland, the US.
For a complete picture of NC-762’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
